Ionis, Otsuka win EU nod for hereditary angioedema therapy

2026-01-21 09:17:01 ET

More on Ionis Pharmaceuticals, Otsuka Holdings

• Ionis: Expected 2026 Launch Of Olezarsen In SHTG To Spur Leap In Revenue Growth
• Ionis Pharmaceuticals, Inc. (IONS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Ionis Pharmaceuticals, Inc. (IONS) Presents at The 67th American Society of Hematology (ASH) Annual Meeting - Slideshow
• Ionis gets FDA breakthrough therapy status for zilganersen
• Sanofi, Lilly among winners of EU drug recommendations this week

Read the full article on Seeking Alpha

For further details see: